Morning Market Gainers

shares surged 43.68 percent to $2.50 after the company reported positive data for multiple compounds from its Mutacin 1140 lantibiotic platform.

shares climbed 26.22 percent to $73.71 after Belgium's Solvay announced its plans to buy Cytec for $5.5 billion.

jumped 20.26 percent to $50.22 after the company reported stronger-than-expected Q2 results.

surged 20.27 percent to $29.73 after the company reported Q2 results and lifted its dividend by 33 percent to $0.04 per share. The company's board authorized a $15 million share repurchase.

gained 15.39 percent to $17.77 on upbeat Q2 results.

shares rose 14.29 percent to $8.00 after the company reported better-than-expected Q2 results.

surged 11.47 percent to $190.92 after the company reported its quarterly financial results.

shares jumped 6.04 percent to $73.83 after the company reported upbeat Q2 earnings and announced that Chief Executive Mark Templeton will retire.

shares gained 4.77 percent to $118.46 as the company reported better-than-expected earnings for the second quarter and raised its FY15 sales forecast.